Amgen aims to broaden use of Lumakras to other cancers. The company is also conducting a Phase 2 test of its drug in colorectal cancer. The company said that clinical trial is fully enrolled and ...

Amgen Inc. cancer drug, Lumakras, is displayed in its packaging at Thousand Oaks, in California, United States September 10, 2022. Amgen/Handout via REUTERS Purchase Licensing Rights, opens new tab.

LUMAKRAS Met Primary Endpoint of Progression-Free Survival, Demonstrating Superiority Over Standard of Care Docetaxel Chemotherapy, in KRAS G12C-Mutated Non-Small Cell Lung Cancer Detailed Data to ...

Early trial data on Amgen Inc's Lumakras was released on Tuesday by the World Conference on Lung Cancer (WCLC), but meeting organizers decided to hold until Aug. 7 results from a highly ...

--Amgen today announced new combination study results from the Phase 1 b CodeBreaK 101 study, a comprehensive global master protocol trial evaluating the safety and efficacy of LUMAKRAS™, the ...

THOUSAND OAKS, Calif., Aug. 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) will review data ...

Amgen on Thursday reported preliminary results from two clinical trials of its KRAS-blocking cancer drug Lumakras, which showed disappointing tumor response and more side effects.

Amgen’s first-in-class KRAS inhibitor Lumakras has been grabbing attention since even before its approval. Now, after closely watching the drug’s commercial performance in non-small cell lung ...

RELATED: Amgen’s up-and-coming KRAS inhibitor gets a name: Lumakras Amgen's drug candidate is nearing an approval as a second-line therapy for patients with KRAS G12C-mutated locally advanced or ...

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the ...

LUMAKRAS ® (sotorasib) Demonstrated Delayed Time to CNS Progression, Longer CNS PFS and Higher Intracranial ORR vs Docetaxel in Post-Hoc Analysis of Phase 3 CodeBreaK 200 Trial LUMAKRAS Shows ...

Amgen Inc's Lumakras pill reduced the risk of disease progression in patients with advanced lung cancer by 34% compared with chemotherapy in a clinical trial, the company said on Sunday.